Toutes les photos(1)

Principaux documents

SAB2501126

Anti-TNKS (N-terminal) antibody produced in goat

Name: Anti-TNKS (N-terminal) antibody produced in goat
Brand: SIGMA

affinity isolated antibody, buffered aqueous solution

Synonyme(s) :

Anti-PARP-5a, Anti-PARP5A, Anti-PARPL, Anti-TIN1, tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Code UNSPSC :

12352203

Nomenclature NACRES :

NA.41

Source biologique

goat

Niveau de qualité

100

Conjugué

unconjugated

Forme d'anticorps

affinity isolated antibody

Type de produit anticorps

primary antibodies

Clone

polyclonal

Forme

buffered aqueous solution

Espèces réactives

human

Technique(s)

western blot: suitable

Numéro d'accès UniProt

O95271

Conditions d'expédition

dry ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

human ... TNKS(8658)

Description générale

The gene TNKS (tankyrase) is mapped to human chromosome 8p23.1. It belongs to the PARP (poly (ADP-ribose) polymerase) family of proteins and is responsible for addition of poly (ADP-ribose) (PAR) to substrate proteins. The TNKS protein contains ankyrin repeats and a sterile α-motif (SAM).

Immunogène

Peptide with sequence RECOMBINANT, from the N Terminal Region of the protein sequence according to NP_003738.2.

Actions biochimiques/physiologiques

TNKS (tankyrase) is a regulator of Wnt-signaling. It negatively regulates Axin1, thereby suppressing β-catenin degradation and causing hyperactivation of Wnt/β-catenin signaling. TNKS controls cell death and telomere length. It might also be associated with osteoarthritis. In murine lung cancer model, silencing of this gene reduces lung cancer cell growth. Application of TNKS inhibitor suppresses growth of hepatocellular carcinoma cells. Absence of TNKS activity helps in replication of human cytomegalovirus (HCMV).

Caractéristiques et avantages

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Forme physique

Supplied at 0.5 mg/mL in Tris saline with 0.02% sodium azide and 0.5% bovine serum albumin.

Vous ne trouvez pas le bon produit ?

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

12 - Non Combustible Liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Genetic variants in eleven telomere-associated genes and the risk of incident cardio/cerebrovascular disease: The Women's Genome Health Study.

Zee RY, et al.

Clinica Chimica Acta; International Journal of Clinical Chemistry, 412, 199-202 (2011)

Tankyrase 1 polymorphism associated with an increased risk in developing non-small cell lung cancer in a Chinese population: a proof-of-principle study.

Wang Y, et al.

International Journal of Clinical and Experimental Pathology, 8, 10500-10511 (2015)

A genome-wide association study of copy-number variation identifies putative loci associated with osteoarthritis in Koreans.

Moon S, et al.

BMC Musculoskelet. Disord., 16, 76-76 (2015)

E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.

Sharon McGonigle et al.

Oncotarget, 6(38), 41307-41323 (2015-10-30)

Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have demonstrated clinical proof of concept for cancer treatment. Here, we describe the development of the novel PARP inhibitor E7449, a potent PARP1/2

Tankyrase inhibitors attenuate WNT/?-catenin signaling and inhibit growth of hepatocellular carcinoma cells.

Ma L, et al.

Oncotarget, 6, 25390-25401 (2015)

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique